Qingdao Baheal Medical INC. (SHE:301015)

China · Delayed Price · Currency is CNY

25.68

+0.64 (2.56%)

Sep 30, 2026, 3:04 PM CST

Market Cap	13.50B -6.5%
Revenue (ttm)	7.31B -6.9%
Net Income	536.22M +18.6%
EPS	1.00 +17.2%
Shares Out	525.62M
PE Ratio	25.75
Forward PE	23.56
Dividend	0.57 (2.22%)
Ex-Dividend Date	Jun 1, 2026

Volume	6,498,400
Open	26.10
Previous Close	25.04
Day's Range	24.91 - 26.10
52-Week Range	18.40 - 28.77
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHE:301015

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical ... [Read more]

Industry Medical Distribution

Sector Healthcare

Founded 2005

Employees 2,493

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301015

Full Company Profile

Financial Performance

In 2025, SHE:301015's revenue was 7.51 billion, a decrease of -7.26% compared to the previous year's 8.09 billion. Earnings were 474.69 million, a decrease of -31.36%.

Financial Statements